GoldenCare

Small molecule

CCDA Research Group, Inc.

GoldenCare is one of 20 small molecule programs targeting Bacterial Vaginosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial VaginosisActive, not recruiting

Bacterial VaginosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Bacterial Vaginosis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

25 2

Acanya

Pfizer

Approved

3 3

Decadron

AAspen Global Incorporated

Approved

—4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Mycostatin

Lactobacillus Acidophilus

UUniversiteit Antwerpen

Approved

1 7

Tindamax

MMission Pharmacal

Phase 3

3 8

Lactoferrin

UUniversità degli Studi di Ferrara

Phase 3

1 9

Conventional

PPopulation Health Research Institute

Phase 3

1 10

Lactoserum

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Vaginosis1 trial

GoldenCareTM for the Treatment of Bacterial Vaginosis

Terminated·CCDA Research Group, Inc.·Phase 1/2·NCT01762670·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GoldenCare. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GoldenCare compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GoldenCare. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CDA Research Group, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCDA Research Group, Inc.

GoldenCare

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News